Moloney Securities Asset Management LLC Sells 4,103 Shares of Novo Nordisk A/S (NYSE:NVO)

Moloney Securities Asset Management LLC cut its stake in Novo Nordisk A/S (NYSE:NVO) by 27.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,808 shares of the company’s stock after selling 4,103 shares during the period. Moloney Securities Asset Management LLC’s holdings in Novo Nordisk A/S were worth $1,287,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of NVO. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S in the second quarter worth about $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth approximately $26,000. Gilliland Jeter Wealth Management LLC grew its position in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. grew its position in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the period. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Up 0.4 %

Shares of NYSE NVO opened at $110.15 on Wednesday. The stock has a market cap of $494.30 billion, a P/E ratio of 37.72, a P/E/G ratio of 1.46 and a beta of 0.42. The firm has a 50 day moving average price of $123.24 and a 200 day moving average price of $130.76. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The company had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Analysts expect that Novo Nordisk A/S will post 3.01 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NVO. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, October 10th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.